DW-1704 is under clinical development by Daewon Pharmaceutical and currently in Phase III for Chronic Cerebrospinal Venous Insufficiency (CCSVI). According to GlobalData, Phase III drugs for Chronic Cerebrospinal Venous Insufficiency (CCSVI) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the DW-1704 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DW-1704 overview
DW-1704 is under development for the treatment of chronic venous insufficiency or lymphatic insufficiency. The drug candidate is an incrementally modified drug (IMD).
It was also under development for the treatment of cardiovascular diseases.
Daewon Pharmaceutical overview
Daewon Pharm Co Ltd (Daewon) is a Pharmaceutical company. It manufactures and supplies pharmaceutical and medicinal products. The company offers antipyretics, analgesics and anti-inflammatory drugs, antimicrobial drugs, respiratory drugs, cardiovascular drugs, gastrointestinal drugs, and antidiabetic drugs. Daewon provides oramin-f soft capsule, pelubi tablet, aquafol injection, megex-i suspension, trigel suspension and tablet, and metran capsule. The company offers products in form of tablets, solutions, film coated tablets, hard capsules, vial and ampoule, soft capsules, and sugar coated tablets. Daewon conducts research in areas of DDS research, drug efficacy evaluation research, synthesis molecules, and botanical drug research, and biologics research. The company markets its products in China, Vietnam, Taiwan, Singapore, Hong Kong, Japan, Mongolia, Malaysia, Cambodia, Myanmar, South Korea, the Philippines, and Indonesia, among others. Daewon is headquartered in Seoul, South Korea.
For a complete picture of DW-1704’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
